COGENT BIOSCIENCES
Cogent Biosciences uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. Unum’s lead program, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, is expected to enter Phase I clinical testing in the coming months to assess safety and efficacy. Unum is seeking partners interested in using the ACTR technology to arm proprietary tumor-specific antibodies with a T-cell to improve their therapeutic potential. The company is headquartered in Cambridge, Massachusetts.
COGENT BIOSCIENCES
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2014-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.cogentbio.com
Total Employee:
101+
Status:
Active
Contact:
(617) 843-5032
Email Addresses:
[email protected]
Total Funding:
432.7 M USD
Technology used in webpage:
SPF Domain Not Resolving Microsoft Exchange Online Amazon Office 365 Mail IPv6 ReCAPTCHA GoDaddy DNS ReCAPTCHA V2 AWS Global Accelerator
Similar Organizations
Rakuten Medical
Rakuten Medical is a Bio-technology Company.
Remix Therapeutics
Remix Therapeutics is a biotechnology company.
Urovant Sciences
Urovant Sciences is a global biopharmaceutical company focused on developing novel therapies for urologic conditions.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2020-07-06 | Kiq | Kiq acquired by Cogent Biosciences | N/A |
Investors List
Logos Capital
Logos Capital investment in Post-IPO Equity - Cogent Biosciences
Commodore Capital
Commodore Capital investment in Post-IPO Equity - Cogent Biosciences
Venrock Healthcare Capital Partners
Venrock Healthcare Capital Partners investment in Post-IPO Equity - Cogent Biosciences
Perceptive Advisors
Perceptive Advisors investment in Post-IPO Equity - Cogent Biosciences
RTW Investments LLC
RTW Investments LLC investment in Post-IPO Equity - Cogent Biosciences
Samsara BioCapital
Samsara BioCapital investment in Post-IPO Equity - Cogent Biosciences
Atlas Venture
Atlas Venture investment in Post-IPO Equity - Cogent Biosciences
OrbiMed
OrbiMed investment in Post-IPO Equity - Cogent Biosciences
Ally Bridge Group
Ally Bridge Group investment in Post-IPO Equity - Cogent Biosciences
BVF Partners
BVF Partners investment in Post-IPO Equity - Cogent Biosciences
Official Site Inspections
http://www.cogentbio.com Semrush global rank: 4.99 M Semrush visits lastest month: 1.69 K
- Host name: 44.255.196.104.bc.googleusercontent.com
- IP address: 104.196.255.44
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Cogent Biosciences" on Search Engine
About – Cogent Biosciences
The Cogent team is driven to discover and develop novel precision medicines. Beginning with bezuclastinib, we strive to improve the lives of patients fighting rare, genetically …See details»
Overview | Cogent Biosciences, Inc.
Corporate Profile. Cogent Biosciences is a biotechnology company focused on developing novel precision therapies to treat a broad range of patients with unmet medical needs. …See details»
Cogent Biosciences Announces Creation of Cogent Research Team
Apr 14, 2021 By: Colorado BioScience Association Date: 04/14/2021. Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing …See details»
Pipelines & Targets – Cogent Biosciences
Pipeline. We strive to develop innovative therapies by strategically focusing on genetically defined diseases. Our clinical pipeline is focused on bezuclastinib, a highly selective and …See details»
Research – Cogent Biosciences
Research – Cogent Biosciences. Discovering New Precision Medicines. Our Science. Building on an exceptional track record of innovation, this team brings a wealth of cross …See details»
Cogent Biosciences Reports Recent Business Highlights and …
CAMBRIDGE, Mass. and BOULDER, Colo., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on …See details»
Cogent Biosciences Reports Recent Business Highlights and …
May 10, 2022 CAMBRIDGE, Mass. and BOULDER, Colo., May 10, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company …See details»
Cogent Biosciences Provides Corporate Updates, Fourth Quarter …
CAMBRIDGE, Mass. and BOULDER, Colo., March 15, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on …See details»
Cogent Biosciences - Crunchbase Company Profile & Funding
Cogent Biosciences is a biotechnology company that develops therapies for solid cancer tumors. Waltham, Massachusetts, United States. 101-250. Post-IPO Equity. Public. …See details»
Cogent Biosciences Announces Creation of Cogent Research Team
Apr 6, 2021 BOULDER, Colo. and CAMBRIDGE, Mass., April 6, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on …See details»
Cogent Biosciences Reports Recent Business Highlights and …
May 9, 2023 WALTHAM, Mass. and BOULDER, Colo., May 09, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company …See details»
Cogent Biosciences, Inc.: Drug pipelines, Patents, Clinical trials ...
Oct 1, 2023 Cogent Biosciences, Inc.: Drug pipelines, Patents, Clinical trials - Synapse. Public Company |. 2014 |. Massachusetts, United States |. NASDAQ: COGT. | …See details»
Cogent Biosciences Reports First Quarter 2024 Financial Results
May 7, 2024 Cogent Biosciences, Inc. Tue, May 7, 2024, 8:00 AM 8 min read. In this article: COGT. Cogent Biosciences, Inc. SUMMIT, PEAK and APEX registration …See details»
Cogent Biosciences Announces Oversubscribed $225 Million …
Feb 14, 2024 Cogent Biosciences Announces Oversubscribed $225 Million Private Placement. February 14, 2024. PDF Version. Pro-forma cash, cash equivalents and …See details»
Summit: A 3-Part, Phase 2 Study of Bezuclastinib ... - Cogent …
Overview. Multi-center, phase 2, double blind, placebo-controlled, 3-part clinical study evaluating the safety and efficacy of bezuclastinib in patients with NonAdvSM with …See details»
Cogent Biosciences Reports Recent Business Highlights and …
Aug 8, 2023 WALTHAM, Mass. and BOULDER, Colo., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company …See details»
Cogent Biosciences - Funding, Financials, Valuation & Investors
$917.7M. in funding over 10 rounds. Their latest funding was raised on Feb 13, 2024 from a Post-IPO Equity round. Cogent Biosciences is registered under the ticker …See details»
Bezuclastinib – Cogent Biosciences
Cogent is currently enrolling Apex, a Phase 2 clinical trial of bezuclastinib in patients with AdvSM. Apex is an open-label, global, multicenter trial that will evaluate the safety, …See details»
We Think Cogent Biosciences (NASDAQ:COGT) Can Afford To …
2 days ago As at March 2024, Cogent Biosciences had cash of US$436m and no debt. Looking at the last year, the company burnt through US$168m. Therefore, from March …See details»
Cogent Biosciences Archives - NIIMBL
Project organization: Cogent Biosciences. The Excellence in Biopharmaceutical Manufacturing Education and Training (EBMET) ... Organization Type Large industry ( …See details»